Hui G S, Nikaido C, Hashiro C, Kaslow D C, Collins W E
Department of Tropical Medicine, University of Hawaii, Honolulu, Hawaii 96816, USA.
Infect Immun. 1996 May;64(5):1502-9. doi: 10.1128/iai.64.5.1502-1509.1996.
We have shown that conserved B epitopes were immunodominant in animals hyperimmunized with parasite-purified or recombinant merozoite surface protein MSP1 of Plasmodium falciparum. Cross-priming studies also suggested that a conserved T-helper epitope(s) is efficient in inducing the anti-MSP1 antibody response. In this study, we determined whether a similar profile of immune responses was induced during live P. falciparum infections. Naive Aotus monkeys were infected by blood-stage challenge with either one of the two dimorphic MSP1 alleles represented by the FUP and FVO parasites. Sera collected after parasite clearance were analyzed by enzyme-linked immunosorbent assays (ELISAs). Monkeys infected with parasites carrying one allelic form of MSP1 had antibodies that were equally reactive with homologous or heterologous MSP1s. This preferential recognition of conserved epitopes of MSP1 was confirmed by competitive binding ELISAs. Studies with Plasmodium yoelii and P. falciparum show that the C-terminal 19-kDa fragment of MSP1, MSP1(19), is the target of protective immunity. Thus, monkey sera were assayed for recognition with recombinant MSP1(19)s expressing variant and conserved B epitopes. Results of direct and competitive binding ELISAs showed that the anti-MSP1(19) antibodies were also directed primarily against conserved determinants. The similarities between vaccine- or infection-induced antibody responses suggest a possible reciprocal enhancement of the two populations of anti-MSP1 antibodies when a subunit MSP1 vaccine is introduced into populations living in areas where malaria is endemic. This together with previous observations that conserved determinants are important in MSP1-mediated immunity provides an optimistic outlook that a subunit MSP1 vaccine may be effective and practical for field applications in malaria-exposed populations.
我们已经表明,在经恶性疟原虫纯化的或重组裂殖子表面蛋白MSP1超免疫的动物中,保守的B表位具有免疫显性。交叉启动研究还表明,一个保守的T辅助表位在诱导抗MSP1抗体反应方面是有效的。在本研究中,我们确定了在恶性疟原虫活感染期间是否诱导了类似的免疫反应谱。将未感染过的夜猴用代表FUP和FVO寄生虫的两种双态MSP1等位基因之一进行血期攻击感染。在寄生虫清除后收集的血清通过酶联免疫吸附测定(ELISA)进行分析。感染携带一种等位基因形式MSP1的寄生虫的猴子产生的抗体与同源或异源MSP1具有同等反应性。这种对MSP1保守表位的优先识别通过竞争性结合ELISA得到证实。对约氏疟原虫和恶性疟原虫的研究表明,MSP1的C末端19 kDa片段,即MSP1(19),是保护性免疫的靶点。因此,检测了猴血清对表达变异和保守B表位的重组MSP1(19)的识别情况。直接和竞争性结合ELISA的结果表明,抗MSP1(19)抗体也主要针对保守的决定簇。疫苗诱导或感染诱导的抗体反应之间的相似性表明,当将亚单位MSP1疫苗引入疟疾流行地区的人群时,这两种抗MSP1抗体群体可能会相互增强。这与之前关于保守决定簇在MSP1介导的免疫中很重要的观察结果一起,提供了一个乐观的前景,即亚单位MSP1疫苗可能对疟疾暴露人群的现场应用有效且实用。